|Late||et al., Press Conference (Preprint)||death, ↓91.4%, p<0.0001||The Proxa-Rescue AndroCoV Trial|
|RCT 590 hospitalized patients, 294 treated with proxalutamide showing significantly lower mortality and faster recovery.|
|Early||et al., Cureus, doi:10.7759/cureus.13492 (Peer Reviewed)||viral+, ↓92.1%, p<0.0001||Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial|
|RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery.|
|Early||et al., Research Square, doi:10.21203/rs.3.rs-135303/v1 (Preprint)||death, ↓81.1%, p=0.22||Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial|
|RCT 214 male patients in Brazil, 114 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429.|
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to cover all people and all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.